RxDoctor Payments Data

Kathi Lutz

Nurse Practitioner · Columbia, MONPI 1861461071

Payments from drug & device makers

$1,379in general payments, 2019–2025

Across 49 payments — averaging $28.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$280
  • Amgen$210
  • Johnson & Johnson$141
  • Edwards Lifesciences$134
  • Boehringer Ingelheim$117
  • AstraZeneca$107
  • plus $390 from 12 others

What the payments were for

  • Food & beverage$1,36599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,379 in reported general payments places this provider in the 80th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$54,937
Medicare patients
522
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan325$321,399
EliquisApixaban298$235,295
XareltoRivaroxaban166$143,908
FarxigaDapagliflozin Propanediol167$122,086
JardianceEmpagliflozin56$40,952
Repatha SureclickEvolocumab22$15,729
Metoprolol Succinate472$5,818
Potassium Chloride142$2,473
Atorvastatin Calcium246$1,777
Diltiazem 24hr Er (Cd)Diltiazem Hcl74$1,673
Spironolactone316$1,535
Prasugrel Hcl15$1,436
Amlodipine Besylate244$1,379
Torsemide81$1,353
Amiodarone Hcl99$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$45$321,399325 claims
PfizerEliquis$13$235,295298 claims
Johnson & JohnsonXarelto$141$143,908166 claims
AstraZenecaFarxiga$107$122,086167 claims
Boehringer IngelheimJardiance$117$40,95256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →